Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.

Oncotarget - 20 Dec 2016

Broséus Julien, Chen Gaili, Hergalant Sébastien, Ramstein Gérard, Mounier Nicolas, Guéant Jean-Louis, Feugier Pierre, Gisselbrecht Christian, Thieblemont Catherine, Houlgatte Rémi

Abstract excerpt

Despite major advances in first-line treatment, a significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) will experience treatment failure. Prognosis is particularly poor for relapses occurring less than one year after the end of first-line treatment (early relapses/ER) compared to those occurring more than one year after (late relapses/LR). To better understand genomic alterations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Dosage

Share to Lymphoma, Large B-Cell, Diffuse

Share to Predictive Value of Tests

Share to Recurrence

Share to Transcriptome

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 27276707
DOI: 10.18632/oncotarget.9793
PMCID: PMC5356640

Genes

DIABLO
DVL3
HES1
IBTK
MTERF4
PTMS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.PMID 27276707Read ↗

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosisSemantic proximity Read ↗

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.Semantic proximity Read ↗

Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapySemantic proximity Read ↗

Relapse timing is associated with distinct evolutionary dynamics in DLBCLSemantic proximity Read ↗

Genetic background and evolution of relapses in aggressive B-cell lymphomas.Semantic proximity Read ↗

Epigenomic evolution in diffuse large B-cell lymphomasSemantic proximity Read ↗

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.Semantic proximity Read ↗

Genomic alterations and gene expression in primary diffuse large B‐cell lymphomas of immune‐privileged sites: the importance of apoptosis and immunomodulatory pathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.